Department of Nuclear Medicine, University of Ulm, Albert-Einstein-Allee 23, Ulm, Germany.
J Endocrinol Invest. 2012;35(6 Suppl):21-9.
Seventy years after the first successful radioiodine treatment of metastatic differentiated thyroid cancer (DTC), radioiodine (131I) therapy for this type of tumor is still without alternative. During the last decade, some key issues such as individual dosimetry, and preparation of 131I therapy by recombinant human TSH have been addressed, but this has not yet lead to conclusive results; furthermore a number of questions related to indication, preparation, and treatment protocol of 131I therapy still remain unanswered. In this review, we will address the literature pertaining to the latest developments in the field of 131I therapy of advanced DTC and we will give an overview of the state of the art regarding patient preparation, dosimetry, and therapy.
在首次成功应用放射性碘（131I）治疗转移性分化型甲状腺癌（DTC）70 年后，这种肿瘤的 131I 治疗仍然没有替代方法。在过去十年中，已经解决了一些关键问题，如个体剂量测定和用重组人 TSH 制备 131I 治疗，但这尚未得出明确的结果；此外，与 131I 治疗的适应证、准备和治疗方案相关的一些问题仍未得到解答。在这篇综述中，我们将讨论关于晚期 DTC 131I 治疗领域的最新进展的文献，并概述有关患者准备、剂量测定和治疗的最新技术。
